Literature DB >> 20889922

Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9.

Peter Allacher1, Christina K Baumgartner, Aniko G Pordes, Rafi U Ahmad, Hans Peter Schwarz, Birgit M Reipert.   

Abstract

Factor VIII (FVIII)-specific memory B cells are essential components for regulating anamnestic antibody responses against FVIII in hemophilia A with FVIII inhibitors. We asked how stimulation and inhibition of FVIII-specific memory B cells by low and high concentrations of FVIII, respectively, are affected by concurrent activation of the innate immune system. Using CD138(-) spleen cells from hemophilic mice treated with FVIII to study restimulation and differentiation of memory B cells in vitro, we tested modulating activities of agonists for Toll-like receptors (TLRs) 2, 3, 4, 5, 7, and 9. Ligands for TLR7 and 9 were most effective. They not only amplified FVIII-specific memory responses in the presence of stimulating concentrations of FVIII, but also countered inhibition in the presence of inhibitory concentrations of FVIII. Notably, CpG oligodeoxynucleotide (CpG-ODN), a ligand for TLR9, expressed biphasic effects. It amplified memory responses at low concentrations and inhibited memory responses at high concentrations, both in vitro and in vivo. Both stimulatory and inhibitory activities of CpG-ODN resulted from specific interactions with TLR9. Despite their strong immunomodulatory effects in the presence of FVIII, ligands for TLR induced negligible restimulation in the absence of FVIII in vitro and no restimulation in the absence of FVIII in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20889922     DOI: 10.1182/blood-2010-06-289009

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells.

Authors:  Xiaomei Wang; Babak Moghimi; Irene Zolotukhin; Laurence M Morel; Ou Cao; Roland W Herzog
Journal:  Mol Ther       Date:  2014-03-10       Impact factor: 11.454

2.  IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.

Authors:  Davide Matino; Marco Gargaro; Elena Santagostino; Matteo N D Di Minno; Giancarlo Castaman; Massimo Morfini; Angiola Rocino; Maria E Mancuso; Giovanni Di Minno; Antonio Coppola; Vincenzo N Talesa; Claudia Volpi; Carmine Vacca; Ciriana Orabona; Rossana Iannitti; Maria G Mazzucconi; Cristina Santoro; Antonella Tosti; Sara Chiappalupi; Guglielmo Sorci; Giuseppe Tagariello; Donata Belvini; Paolo Radossi; Raffaele Landolfi; Dietmar Fuchs; Louis Boon; Matteo Pirro; Emanuela Marchesini; Ursula Grohmann; Paolo Puccetti; Alfonso Iorio; Francesca Fallarino
Journal:  J Clin Invest       Date:  2015-08-31       Impact factor: 14.808

Review 3.  Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A.

Authors:  Alexandra Sherman; Moanaro Biswas; Roland W Herzog
Journal:  Front Immunol       Date:  2017-11-24       Impact factor: 7.561

4.  The TLR9 ligand CpG ODN 2006 is a poor adjuvant for the induction of de novo CD8+ T-cell responses in vitro.

Authors:  Victor Appay; Francesco Nicoli; Laura Papagno; Nozomi Kuse; Anna Lissina; Emma Gostick; David A Price
Journal:  Sci Rep       Date:  2020-07-15       Impact factor: 4.379

Review 5.  Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1.

Authors:  Davide Matino; Sajjad Afraz; George Zhao; Paul Tieu; Marco Gargaro; Francesca Fallarino; Alfonso Iorio
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

6.  Risk factors for inhibitors in hemophilia A based on RNA-seq and DNA methylation.

Authors:  Wei Liu; Cuicui Lyu; Wentian Wang; Feng Xue; Lingling Chen; Huiyuan Li; Ying Chi; Yueshen Ma; Runhui Wu; Yunhai Fang; Lei Zhang; Renchi Yang
Journal:  Res Pract Thromb Haemost       Date:  2022-09-05

7.  Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.

Authors:  Federico Mingozzi; Yifeng Chen; Samuel L Murphy; Shyrie C Edmonson; Alex Tai; Sandra D Price; Mark E Metzger; Shangzhen Zhou; J Fraser Wright; Robert E Donahue; Cynthia E Dunbar; Katherine A High
Journal:  Mol Ther       Date:  2012-05-08       Impact factor: 11.454

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.